Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma

Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma
Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma
CME, CPE
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Release Date: July 19, 2017
Expiration Date: July 19, 2018

The addition of new lenalidomide- and bortezomib-based drug regimens for patients with multiple myeloma increases the complexity of pharmacotherapeutic strategies, which must balance response benefit with tolerability. There are a number of comorbidities and treatment-related adverse events that must be appropriately assessed and monitored for, to ensure patient safety and prevent premature discontinuation of therapy. In this activity, Dr. Harvey will discuss hepatic and renal dysfunction, diabetes, and cardiovascular dysfunction, all of which can impact pharmacy-related decisions such as dose-modification, treatment interruption, or administration of concomitant medications.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
Begin, Earn CreditView Only, No Credit